CRISPR-MTB Test: Diagnostic Performance for Tuberculosis in 179 Patients

179 patients were evaluated in a retrospective cohort study comparing a CRISPR-based diagnostic test for Mycobacterium tuberculosis against culture and the GeneXpert MTB/RIF assay. The test demonstrated 79% sensitivity, outperforming culture (33%) and Xpert (66%), with 98% specificity. Jingwen Ai developed this rapid, ultra-sensitive assay for detecting TB in pulmonary and extra-pulmonary clinical samples.

Use Cases

• Benchmarking new diagnostic assays based on sensitivity and specificity metrics from the clinical cohort.
• Evaluating CRISPR-based detection methods for bacterial pathogens based on the described near single-copy sensitivity.
• Comparing diagnostic performance across sample types based on the evaluation in pulmonary and extra-pulmonary tuberculosis samples.

Strengths

• Clinical evaluation involved a cohort of 179 patients.
• Test demonstrated 79% sensitivity and 98% specificity.
• Description provides direct performance comparisons against two established diagnostic methods.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

paperswithcode

Collection Method

Retrospective cohort study of clinical samples.